帕米膦酸二钠葡萄糖注射液致过敏性休克1例分析  

One case of anaphylactic shock caused by pamidronate disodium glucose injection

作　　者：刘猛 方可 严家菊 刘梦 何曼云 魏良兵[2] LIU Meng;FANG Ke;YAN Jiaju;LIU Meng;HE Manyun;WEI Liangbing(Department of Clinical Pharmacy,Affiliated Hospital of West Anhui Health Vocational College,Lu’an Anhui 237008,China;Department of Pharmacy,the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine,Hefei Anhui 230031,China)

机构地区：[1]皖西卫生职业学院附属医院临床药学部,安徽六安237008 [2]安徽中医药大学第一附属医院药学部,安徽合肥230031

出　　处：《中国药物警戒》2024年第10期1172-1174,共3页Chinese Journal of Pharmacovigilance

基　　金：安徽省教育厅高校科学研究项目(2022YJZR002);安徽省高校优秀拔尖人才培育重点项目(gxyqZD2022119)。

摘　　要：目的探讨帕米膦酸二钠致过敏性休克的发生特点,为临床防治不良反应和安全用药提供参考。方法分析1例帕米膦酸二钠导致过敏性休克的病例,根据国家药品不良反应监测中心评价方法进行关联性评价,文献回顾帕米膦酸二钠常见不良反应和致过敏性休克的发病机制,讨论原因及防治措施。结果根据患者的临床表现及药物与用药时间的关联性,考虑帕米膦酸二钠导致过敏性休克可能性大,患者经积极救治后,过敏性休克症状得到缓解。结论临床应用帕米膦酸二钠应警惕发生过敏性休克的风险,用药期间加强不良反应监测,促进临床安全合理用药。Objective To investigate the characteristics of anaphylactic shock triggered by pamidronate disodium in order to provide data for the prevention and treatment of adverse reactions and ensure safe medications.Methods One case of anaphylactic shock induced by pamidronate disodium was reported,with the correlations assessed using the evaluation method recommended by the National Adverse Drug Reaction Monitoring Center.Additionally,literature on the common adverse reactions and pathogenesis related to pamidronate disodium was reviewed to explore the potential causes and preventive strategies.Results The patient’s clinical conditions and the timing of drug administration strongly suggested that pamidronate disodium was the likely cause of anaphylactic shock,so immediate and effective treatment was offered to alleviate the symptoms.Conclusion Clinicians who prescribe pamidronate disodium should be alert to the risk of anaphylaxis.It is crucial to enhance monitoring of adverse reactions and ensure the availability of emergency medications and equipment during treatment.

关 键 词：帕米膦酸二钠 注射液 过敏性休克 严重过敏 药品不良反应 病例报告 

分 类 号：R979.1[医药卫生—药品] R994.11[医药卫生—药学]